Aprotinin reduces the expression of P-selectin on the surface of platelet and leukocyte-platelet conjugates

Artificial Organs

Volumn 22, Issue 12, 1998, Pages 1018-1022

  Inui, Kiyoshige ^a   Shimazaki, Yasuhisa ^a   Watanabe, Takao ^a   Kuraoka, Setsuo ^a   Uesho, Kunihiro ^a   Uchida, Tetsuro ^a   Shiono, Satoshi ^a  

^a YAMAGATA UNIVERSITY   (Japan)

Author keywords

Aprotinin; Cardiopulmonary bypass; P selectin

Indexed keywords

AMINO ACIDS;

ACTIVATED PLATELETS; ADHESION MOLECULES; APROTININ; CARDIOPULMONARY BYPASS; CONTROL GROUPS; LEUCOCYTES; P-SELECTIN; SOLUBLE P; SUPEROXIDE ANIONS; VASCULAR ENDOTHELIUM;

PLATELETS;

APROTININ; CELL ADHESION MOLECULE; PADGEM PROTEIN; SERINE PROTEINASE INHIBITOR;

ADULT; ARTICLE; BLEEDING TENDENCY; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INDUCED HYPOTHERMIA; INFLAMMATION; LEUKOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; VASCULAR ENDOTHELIUM;

EID: 0031647373     PISSN: 0160564X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1594.1998.06181.x     Document Type: Article

References (27)

1. Edmunds LH Jr. Blood-surface interactions during cardiopulmonary bypass. J Cardiovasc Surg 1993;8:404-10.
2. Gu YJ, van Oeveren W, Akkerman C, Boonstra PW, Huyzen RJ, Wildevuur CR. Heparin-coated circuits reduce the inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:917-22.
3. Blauhut B, Gross C, Necek S, Dorn JE, Spath P, Lundsgaad-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101: 958-67.
4. Havel M, Teufelsbauer H, Knoble P, Dalmatiner R, Jaksch P, Zwolfer W, Muller M, Vukovich T. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101:968-72.
5. Kawasuji M, Ueyama K, Sakakibara N, Tedoriya T, Matsunaga Y, Misaki T, Watanabe Y. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 1993;55:1205-9.
6. Lavec J, Savion N, Smolinsky A, Goor DA, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: Electron microscopic study. Ann Thorac Surg 1992;53:477-81.
7. Hamburger SA, McEver RP. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood 1990;75:550-4.
8. Nagata K, Tsuji T, Todoroki N, Katagiri Y, Tanoue K, Yamazaki H, Hanai N, Irimura T. Activated platelets induce superoxide anion release by monocytes and neutrophils through p-selectin (CD62). J Immunol 1993;151:3267-73.
9. 2, leukotriene C4 cooperative synthesis. Thromb Haemost 1994;72:450-6.
10. Mulligan MS, Policy MJ, Bayer RJ, Nunn MF, Paulson JC, Ward PA. Neutrophil-dependent acute lung injury. Requirement for p-selectin (GMP-140). J Clin Invest 1992;90:1600-7.
11. Moat NE, Shore DF, Evans TW. Organ dysfunction and cardiopulmonary bypass: The roll of complement and complement regulatory proteins. Eur J Cardiothorac Surg 1993;7: 563-73.
12. Nilsson L, Nilsson U, Venge P, Johansson O, Tyden H, Aberg T, Nystrom SO. Inflammatory system activation during cardiopulmonary bypass as an indicator of biocompatibility: A randomized comparison of bubble and membrane oxygenators. Scand J Thorac Cardiovasc Surg 1990;24:53-8.
13. Westaby S. Organ dysfunction after cardiopulmonary bypass. A systemic inflammatory reaction initiated by the extracorporeal circuits. Intens Care Med 1987;13:89-95.
14. Bidstrup BP, Royston D, Sapsford RN, Taylor KM. Reduction in blood loss and blood use after cardiopulmonary bypass with high dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
15. Paramo JA, Rifon J, Llorens R, Casares J, Paloma MJ, Rocha E. Intra and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery. Haemostasis 1991;21:58-64.
16. Tanaka K, Takao M, Yuasa H, Kusagawa M, Deguchi K. Alterations in coagulation and fibrinolysis associated with cardiopulmonary bypass during open heart surgery. J Cardiovasc Anesth 1989;3:181-8.
17. Lavee J, Raviv Z, Smolinsky A, Savion N, Varon D, Goor DA, Mohr R. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: Electron microscopic study. Ann Thorac Surg 1993;55:477-81.
18. van Oeveren W, Jansen NJ, Bidstrup BP, Royston D, Westaby S, Neuhof H, Wildevuur CR. Effects of aprotinin on hemostatic mechanism during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
19. van Oeveren W, Harder MP, Roozendaal KJ, Wildvuur CR. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99: 788-96.
20. Heller W, Fuhrer G, Gallimore MJ, Michel J, Hoffemeister HE. Changes in the kallikrein-kinin-system after different dose of regimen of aprotinin during cardiopulmonary bypass operation. Adv Exp Med Biol 1989;1:43-8.
21. Wachtfogel Y, Kucich U, Hach E, Gluszko P, Niewiarowski S, Colman RW, Edmund LH Jr. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106: 1-10.
22. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Dynamics of leukocyte-platelet adhesion in whole blood. Blood 1991;78:1730-7.
23. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Activated and unactivated platelet adhesion to monocytes and neutrophils. Blood 1991;78:1760-9.
24. Rinder CS, Bonan JL, Rinder HM, Mathew J, Hines R, Smith BR. Cardiopulmonary bypass induces leukocyte-platelet adhesion. Blood 1992;79:1201-5.
25. Komai H, Haworth SG. Effect of cardiopulmonary bypass on the circulating level of soluble GMP-140. Ann Thorac Surg 1994;58:478-82.
26. Butler J, Rocker GM, Westaby S. Inflammatory response to cardiopulmonary bypass. Ann Thorac Surg 1993;55:552-9.
27. Inui K. Participation of platelet activating factor in the pulmonary injury during cardiopulmonary bypass. Nippon Kyobu Geka Gakkai 1993;41:238-46.